Results 91 to 100 of about 79,614 (239)
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, Volume 100, Issue S4, Page 88-115, June 2025.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53 mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source
Journal of Hematology & Oncology, 2016 Background Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults. Although improvements in contemporary therapy and development of new treatment strategies have led to dramatic ...
Pei-Jie Shi +4 more
doaj +1 more source
Pediatric Blood &Cancer, Volume 72, Issue 6, June 2025.ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical and clinical activity in ALL.
Andrew E. Place +21 more
wiley +1 more source
대한영상의학회지, 2016 T-cell lymphoblastic lymphoma is a highly aggressive tumor derived from lymphocyte of the thymus, which accounts for 2% of non-Hodgkin's lymphoma. The disease occurs most commonly in adolescent and young adult males.
Tae Ran Ahn +4 more
doaj +1 more source
Acute Lymphoblastic Leukemia Presenting as Acute Vogt-Koyanagi-Harada Syndrome
Case Reports in Ophthalmology, 2020 We aimed to describe a case of acute lymphoblastic leukemia (ALL) that initially presented and was managed as Vogt-Koyanagi-Harada syndrome (VKH). A 62-year-old man was referred for vision loss starting 1 week ago.
Narges Hassanpoor +1 more
doaj +1 more source
European Journal of Haematology, Volume 114, Issue 6, Page 938-952, June 2025.ABSTRACT The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have demonstrated remarkable efficacy, achieving high response rates and minimal residual disease (MRD) negativity ...
Antonella Bruzzese +11 more
wiley +1 more source
Model-based simulation of maintenance therapy of childhood acute lymphoblastic leukemia [PDF]
arXiv, 2019 Acute lymphoblastic leukemia is the most common malignancy in childhood. Successful treatment requires initial high-intensity chemotherapy, followed by low-intensity oral maintenance therapy with oral 6-mercaptopurine (6MP) and methotrexate (MTX) until 2-3 years after disease onset.
arxiv
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Cancer Communications, Volume 45, Issue 5, Page 529-571, May 2025.Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential ...
Mohammad Mahmoudi Gomari +11 more
wiley +1 more source
Hematology, Transfusion and Cell Therapy, 2021 Introduction: Cerebrospinal fluid (CSF) infiltration can be identified at diagnosis and during the course of many hematopoietic malignancies, mainly acute leukemia and aggressive non-Hodgking lymphomas (NHL).
GF Bevilacqua +6 more
doaj
Medicina, 2016 Context: Acute pancreatitis is a inflammatory process of the pancreas. It can be caused by gallstones, metabolic disorders, associated or not with alcohol abuse, or medication.
Renne Rodrigues +3 more
doaj +1 more source